Showing 7,301 - 7,320 results of 26,964 for search '(( 50 ((((nn decrease) OR (we decrease))) OR (a decrease)) ) OR ( 50 mm decrease ))', query time: 0.97s Refine Results
  1. 7301

    Actions to Include in a Farm Environment Plan by Annabel McAleer (15329209)

    Published 2024
    “…This interactive infographic is a compilation of actions to decrease the loss of contaminants from agricultural land. …”
  2. 7302

    Supplementary materials. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  3. 7303

    Gonadal development and sex ratios as a function of TL. by Frederic H. Martini (481487)

    Published 2013
    “…</p> <p>(b) Sex ratios (female:male) as a function of TL. Data were sorted into 50 mm TL intervals. …”
  4. 7304

    Summary of subgroup analysis results. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  5. 7305

    PRISMA Flow Chart 2020. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  6. 7306

    Included and excluded studies. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  7. 7307

    Characteristics of included studies. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  8. 7308

    Extraction data table. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  9. 7309

    Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms by JunHyuk Kim (21235657)

    Published 2025
    “…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
  10. 7310

    Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms by JunHyuk Kim (21235657)

    Published 2025
    “…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
  11. 7311
  12. 7312
  13. 7313

    Effects of Common Polymorphisms rs11614913 in <em>miR-196a2</em> and rs2910164 in <em>miR-146a</em> on Cancer Susceptibility: A Meta-Analysis by Wei Xu (28953)

    Published 2011
    “…Rs11614913 in <em>miR-196a2</em> and rs2910164 in <em>miR-146a</em> are shown to associate with increased/decreased cancer risk. …”
  14. 7314

    MiR-29a targets PTEN. by Guangyao Kong (185282)

    Published 2011
    “…Empty pcDNA3.0 plasmid (200 ng) was used as a negative control. (C) Luciferase reporter gene assay showed that the decreased luciferase activities of PTEN 3′UTR reporter (PTEN 3′UTR-1 or PTEN 3′UTR-2) in HepG2 cells mediated by miR-29a overexpression (200 ng) was rescued by a miR-29a inhibitor in a dose dependent manner (30, 50, and 100 nM). …”
  15. 7315

    Modulation of Aβ-induced deleterious signaling. by Tao Yang (184280)

    Published 2008
    “…<p>For each study, LM11A-24 and -31 were present at 100 nM and NGF at 50 or 100 ng/ml. …”
  16. 7316

    Identity between upstream stripes and Alu-sequences and their expression as a function of upstream poly(A)-segments of the GA-sequences. by Guenter Albrecht-Buehler (266704)

    Published 2009
    “…<p>The GPxIs show portions of the GA-complexes of human chr.1 after sorting them by the decreasing size of poly(A)-segments at the upstream end of the GA-sequences. …”
  17. 7317

    CORT triggered a slow-onset increase in GluN2A/GluN2B ratio. by Yiu Chung Tse (340737)

    Published 2013
    “…<p>(<b>A</b>) Plots of NMDAR-EPSC amplitude from control and CORT-treated slices against time show decreased EPSC amplitude after sequential application of Ro (1 µM; for 30 min) and a mixture of Ro and a subunit non-selective NMDAR antagonist APV (50 µM; for 10 min). …”
  18. 7318

    Effects of sialidase treatment on substantia nigra dopamine neurons. by Jay S. Schneider (671374)

    Published 2015
    “…<p>Sub-acute MPTP treatment (aCSF-MPTP) resulted in significant decreases in the number of tyrosine hydroxylase immunopositive (A.) and Nissl-stained (B.) cells in the substantia nigra pars compacta. …”
  19. 7319

    Data selection by changes in the firing rate. by Huu Hoang (9188747)

    Published 2020
    “…<p>A: the histograms of firing rate change by drug treatments (decreased by CBX and increased by PIX) compared to the CON condition. …”
  20. 7320

    Targeting hTERT Promoter G‑Quadruplex DNA Structures with Small-Molecule Ligand to Downregulate hTERT Expression for Triple-Negative Breast Cancer Therapy by Wei Long (411482)

    Published 2024
    “…Human telomerase reverse transcriptase (hTERT) may have noncanonical functions in transcriptional regulation and metabolic reprogramming in cancer cells, but it is a challenging target. We thus developed small-molecule ligands targeting hTERT promoter G-quadruplex DNA structures (hTERT G4) to downregulate hTERT expression. …”